Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015

Conditions

Acute Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders

Brief summary

HEMATO-BIO-IPC-2013-015 is a monocenter prospective longitudinal study. Our aim is to define predictive clinical and biological factors in acute leukemia, myelodysplastic syndromes and myeloproliferative disorders by using genomics, genetics and epigenetics, in vitro and in vivo drug sensitivity studies,and translational immonulogy and immunomonitoring studies. HEMATO-BIO primary outcome measure is to identify molecular, genomic and epigenetic, pharmacologic and immunophenotypic alteration in acute leukemia, myelodysplastic syndromes and myeloproliferative disorders by collecting, at diagnosis and/or complete remission and/or relapse: * tumor samples: marrow aspiration, blood sampling. * non-tumor samples: skin biopsy, buccal swab . from 650 patients treated at our cancer center.

Sylvain Garciaz, Camille Montersino, Maxence Bourgoin, Arnaud Jacquel, Rémy Castellano et al. (12 authors)

British Journal of Haematology2025-06-06

10.1111/bjh.20195

Dasatinib Overcomes AML Resistance to BCL2 Inhibition By Indirectly Inhibiting MCL1: From <i>Ex Vivo</i> drug Sensitivity/Resistance Profiling to a Phase II Clinical Trial: A Hemato-BIO Study

Sylvain Garciaz, Rémy Castellano, Arnaud Jacquel, Arnaud Guillé, Maxence Bourgoin et al. (11 authors)

Blood2024-11-05

10.1182/blood-2024-207352

Genetic deletion of JAM-C in preleukemic cells rewires leukemic stem cell gene expression program in AML

Julien M. P. Grenier, Céline Testut, Matthieu Bal, Florence Bardin, Maria De Grandis et al. (20 authors)

Blood Advances2024-07-023 citations

10.1182/bloodadvances.2023011747

High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome.

Chretien AS, Devillier R, Granjeaud S, Cordier C, Demerle C, Salem N, Wlosik J, Orlanducci F, Gorvel L, Fattori S, Hospital MA, Pakradouni J, Gregori E, Paul M, Rochigneux P, Pagliardini T, Morey M, Fauriat C, Dulphy N, Toubert A, Luche H, Malissen M, Blaise D, Nunès JA, Vey N, Olive D.

2021-06-0148 citations

10.1073/pnas.2020459118

Interventions

OTHERBlood sampling

Longitudinal (3 stages of the disease)

OTHERBone marrow aspirate

Longitudinal (3 stages of the disease)

OTHERSkin biopsy

Single biopsy (optional)

OTHERBuccal swab

Single sampling.

Study design

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* acute leukemia, myelodysplastic syndrome or myeloproliferative disease * age \> 18 * affiliated to the French Social Security Systm * signed informed consent

Exclusion criteria

* emergency * patients deprived of liberty or placed under the authority of a tutor

Design outcomes

Primary

Measure	Time frame
Acute leukemia/ Myeloproliferative/ myelodysplastic syndrome cells profiling (molecular analysis, epigenetic profile, drug sensitivity profile,immunophenotyping)	up to 8 years

Secondary

Measure	Time frame
Compare cancer and non-tumor cells genome	up to 8 years
Correlation between molecular alteration and clinical characteristics(diagnosis,cytogenetics,overall survival, progression free survival)	up to 8 years

Countries

France

Contacts

Primary ContactDominique Genre, MD

drci.up@ipc.unicancer.fr+33491223778

Backup ContactJihane Pakradouni, PharmD,PhD